PBP1502 (Adalimumab biosimilar)

Tuznue™ is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue™ is indicated for the treatment of patients with HER2-positive metastatic breas...

This is a biosimilar candidate of bevacizumab (Avastin®). Bevacizumab is used to treat many different types of cancer (often as first-line therapy) including metastatic colorectal cancer, non-small-cell lung cancer (NSCLC), renal cell cancer, ovarian cancer and metastatic breast cancer. Global Phase 3 ...

PBP1510 is a first-in-class monoclonal antibody drug developed by Prestige Biopharma Limited against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein that is overexpressed in pancreatic adenocarcinoma. PAUF is involved in promoting tumor growth, invasion, and metastasis, in the evasion o...